| Prev Close: | 45.69 |
|---|---|
| Open: | 45.90 |
| Bid: | 45.72 x 100 |
| Ask: | 45.80 x 100 |
| 1y Target Est: | 50.43 |
| Beta: | 0.38 |
| Next Earnings Date: | N/A |
| Day's Range: | 45.49 - 46.01 |
|---|---|
| 52wk Range: | 37.02 - 48.79 |
| Volume: | 14,246,141 |
| Avg Vol (3m): | 16,718,600 |
| Market Cap: | 138.21B |
| P/E (ttm): | 22.86 |
| EPS (ttm): | 2.00 |
| Div & Yield: | 1.72 (3.60%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
How Health Care Is Mining, Using Your DataBig Data Download- Stocks Retreat From Highs, Fed Stays FlexibleHot Stock Minute
- Merck's CEO Discusses Q1 2013 Results - Earnings Call TranscriptSeeking Alpha
- ADP Payroll Disappoints; Apple’s Record-Breaker; New T-MobileHot Stock Minute
Headlines
- 3 Blue Chips with Big Buyback Plansat Motley Fool(Thu 12:33PM EDT)
- Mapping Merck: Q1 And Beyondat Seeking Alpha(Thu 12:02PM EDT)
- Are These The Biotech Stars Of Tomorrow?The StreetAuthority Network(Thu 11:00AM EDT)
- Gilead reports positive test results from hepatitis C treatment studiesat MarketWatch(Thu 10:56AM EDT)
- US STOCKS-Wall Street gains on data, ECB rate cutat Reuters(Thu 10:26AM EDT)
- US STOCKS-Wall Street set to open slightly higher on data, ECB cutat Reuters(Thu 9:13AM EDT)
- Company News for May 2, 2013Zacks(Thu 8:45AM EDT)
- US STOCKS-Futures extend gains after ECB rate cutat Reuters(Thu 8:18AM EDT)
- US STOCKS-Futures gain ahead of ECB rate decisionat Reuters(Thu 7:24AM EDT)
- Dow Falls on Employment Worriesat Motley Fool(Wed, May 1)
- Merck & Co Earnings Call Nuggets: PD-1 Program and Share Repurchasesat Wall St. Cheat Sheet(Wed, May 1)
- Merck Lowers 2013 Guidanceat Motley Fool(Wed, May 1)
- [video] No Huddle Offense: Profits In the Pipeline?at CNBC(Wed, May 1)
- [video] Am I Diversified? Cramer's Callat CNBC(Wed, May 1)
- An Animal of a Quarterat Motley Fool(Wed, May 1)
Press Releases
- Merck Announces First-Quarter 2013 Financial ResultsBusiness Wire(Wed, May 1)
- Merck Announces New $15 Billion Share Repurchase ProgramBusiness Wire(Wed, May 1)
- Merck Wins FOSAMAX® (alendronate sodium) Federal Bellwether Trial Involving Atypical Femur Fracture ClaimsBusiness Wire(Mon, Apr 29)
Reports
- MRK: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(May 2)
- Thomson Reuters Stock Report - MERCK & CO. , INC. (MRK-N)Thomson Reuters Stock Report(May 2)
- MRK - Merck & Co Inc - Rated a Hold - Research Report by ASRAlpha Street Research(Apr 29)